ArticleVaccine2011
Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.PloS one · 2013Trial
- Protection AgainstVaccines · 2026Article
- Article
- Heterologous signal peptide grafting enhances the immune efficacy of Salmonella vectors delivering hemagglutinin against H7N9 avian influenza virus.Veterinary research · 2025Article
- Article
- Oral Immunization with AttenuatedBiomolecules · 2023Article
- An mRNA-Based Multiple Antigenic Gene Expression System Delivered by EngineeredPharmaceutics · 2023Article
- Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria.Cancers · 2023Article
- Protective immunity enhancedFrontiers in immunology · 2022Article
- Oral Delivery of a DNA Vaccine Expressing the PrM and E Genes: A Promising Vaccine Strategy against Flavivirus in Ducks.Scientific reports · 2018Article
- The efficacy, biodistribution and safety of an inhibin DNA vaccine delivered by attenuated Salmonella choleraesuis.Microbial biotechnology · 2018Article
- An Influenza HA and M2e Based Vaccine Delivered by a Novel AttenuatedFrontiers in microbiology · 2017Article
- Article
- Bacteria in Cancer Therapy: Renaissance of an Old Concept.International journal of microbiology · 2016Review
- Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.Plant cell reports · 2015Article
- Article
- Immune responses to oral and IM administration of M2e-Hsp70 construct.Veterinary research communications · 2014Article
- Development ofVaccines · 2014Article
- Live bacterial vaccine vectors: an overview.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2014Review
- New technologies in developing recombinant attenuated Salmonella vaccine vectors.Microbial pathogenesis · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Orally administered recombinant attenuated Salmonella vaccines (RASVs) elicit humoral and mucosal immune responses against the immunizing antigen. The challenge in developing an effective vaccine against a virus or an intracellular bacterium delivered by RASVs is to introduce the protective antigen inside the host cell cytoplasm for presentation to MHC-I molecules for an efficient cell mediated immune response. To target the influenza nucleoprotein (NP) into the host cell cytosol, we constructed a regulated delayed lysis in vivo RASV strain χ11246(pYA4858) encoding influenza NP with a chromosomal deletion of the sifA gene to enable it to escape from the endosome prior to lysis. Oral immunization of mice with χ11246(pYA4858) (SifA⁻) with 3 booster immunizations resulted in complete protection (100%) against a lethal influenza virus (rWSN) challenge (100 LD₅₀) compared to 25% survival of mice immunized with the isogenic χ11017(pYA4858) (SifA⁺) strain. Reducing the number of booster immunizations with χ11246(pYA4858) from 3 to 2 resulted in 66% survival of mice challenged with rWSN (100 LD₅₀). Immunization with χ11246(pYA4858) via different routes provided protection in 80% orally, 100% intranasally and 100% intraperitoneally immunized mice against rWSN (100 LD₅₀). A Th1 type immune response was elicited against influenza NP in all experiments. IFN-γ secreting NP₁₄₇₋₁₅₅ specific T cells were not found to be correlated with protection. The role of antigen-specific CD8⁺ T cells remains to be determined. To conclude, we showed that Salmonella can be designed to deliver antigen(s) to the host cell cytosol for presumably class I presentation for the induction of protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.